At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Lapatinib and Paclitaxeldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
In Brief
A Phase 1 clinical trial evaluating Lapatinib and Paclitaxel for Ovarian Cancer. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartMar 2021
Primary CompletionMay 2024
TodayJul 2026
First PostedOct 29, 2020
Enrollment StartMar 17, 2021
Primary CompletionMay 17, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.7 years ago
Interventions
Lapatinib and Paclitaxeldrug
Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.